OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer

- May 11th, 2016

OncBioMune Pharmaceuticals (OTCMKTS:OBMP) announced an update on the clinical advancement of ProscaVax, the Company’s novel cancer vaccine in development for prostate cancer.

OncBioMune Pharmaceuticals (OTCMKTS:OBMP) announced an update on the clinical advancement of ProscaVax, the Company’s novel cancer vaccine in development for prostate cancer.
As quoted in the press release:

In the United States, a Phase 1a/1b trial of ProscaVax is ongoing at the Veterans’ Administration Medical Center and the University of California San Diego Medical School, both in La Jolla, California. 16 of 20 patients have been enrolled in the 1a portion of the study with clinical data analyzed on 12 patients so far. Data to date shows ProscaVax to have a meaningful impact in reducing the rise in PSA (prostate specific antigen) levels in 60% (6 out of 10) of patients receiving six vaccinations and an increased immune response in 89% (8 out of 9) patients at 31 weeks after administration of the vaccine. No ProscaVax-related adverse events have occurred during the trial, matching the results from prior studies of ProscaVax and other vaccines built upon the vaccine platform. As previously disclosed, the data is compelling enough that OncBioMune has elected to forego the Phase 1b component and advance ProscaVax into two, separate Phase 2 studies.
The Company is preparing to initiate one of the Phase 2 trials at one of the world’s leading university hospital networks located in the Northeast U.S. The trial will enroll patients at presentation of prostate cancer, a time where there are currently no therapeutic options other than surgery or radiation therapies, both of which have well documented morbidity issues. To the best of the Company’s knowledge, ProscaVax will be the only cancer vaccine in the world in mid-stage clinical research evaluating safety and efficacy in prostate cancer patients in the “active surveillance” category.

OncBioMune CEO, Dr. Jonathan Head, stated:

Addressing prostate cancer at disease presentation is a key in developing a front-line defense to treat the disease, but no company has successfully accomplished this. We have published testimonials from early recipients of ProscaVax attributing their health and longevity to ProscaVax, testimonials that we hope can be reinforced with larger studies. Dr. Bubley has expressed his excitement for the trial, which in itself is an extreme vote of confidence for ProscaVax, and we greatly look forward to commencing the trial.

Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.

Leave a Reply